The price of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares last traded on Wall Street fell -0.79% to $139.40.
NBIX stock price is now 0.52% away from the 50-day moving average and 11.34% away from the 200-day moving average. The market capitalization of the company currently stands at $14.03B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $140 to $170, Wells Fargo Upgraded its rating from Equal Weight to Overweight for Neurocrine Biosciences, Inc. (NASDAQ: NBIX). , while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, POPS RICHARD F, Director sold 2,100 shares of the company’s stock on May 17 ’24. The stock was sold for $297,860 at an average price of $141.84. Upon completion of the transaction, the Director now directly owns 31,611 shares in the company, valued at $4.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 17 ’24, Director Sharp Shalini sold 1,106 shares of the business’s stock. A total of $156,943 was realized by selling the stock at an average price of $141.90. This leaves the insider owning 994 shares of the company worth $0.14 million. A total of 2.24% of the company’s stock is owned by insiders.
During the past 12 months, Neurocrine Biosciences, Inc. has had a low of $89.04 and a high of $148.37. As of last week, the company has a debt-to-equity ratio of 0.23, a current ratio of 2.52, and a quick ratio of 2.47. According to the stock market information, the enterprise value for the company is $13228929024, which is based on a 38.32 price-to-earnings ratio, a 2.13 price-to-earnings-growth ratio, and a beta of 0.36. The fifty day moving average price for NBIX is $138.6862 and a two-hundred day moving average price translates $125.3873 for the stock.
The latest earnings results from Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was released for 2024-03-31. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at 0.95, beating analysts’ expectations of 0.78 by 0.17. This compares to -$0.79 EPS in the same period last year. The net profit margin was 18.65% and return on equity was 18.16% for NBIX. The company reported revenue of $515.3 million for the quarter, compared to $420.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.57 percent. For the current quarter, analysts expect NBIX to generate $547.37M in revenue.
